Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC
Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer…